Loading…
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225. The company has collaborations NorthStar to develop radio-immuno-therapeutics targeting severe COVID-19; Excel Diagnostics and Nuclear Oncology Center, for the investigational imaging agent MNPR-101-Zr and investigational therapeutic agent MNPR-101-Lu; license agreement with Alexion to develop and commercialize ALXN1840, a drug candidate for Wilson disease. The company was founded in 2014 and is headquartered in Wilmette, Illinois.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $0M | $-17M | $-14M | $-12M | -10.0% | - | - |
| 2024 | $0M | $-16M | $-16M | $-6M | -28.3% | - | - |
| 2023 | $0M | $-9M | $-8M | $-8M | -150.4% | - | - |
| 2022 | $0M | $-11M | $-11M | $-7M | -104.2% | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | 0 |
| Operating Expense | 10.54 | 8.83 | 16.16 | 16.70 |
| Operating Income | -10.54 | -8.83 | -16.16 | -16.70 |
| EBITDA | -10.54 | -8.83 | -16.16 | -16.70 |
| EBIT | -10.54 | -8.83 | -16.16 | -16.70 |
| Pretax Income | -10.52 | -8.40 | -15.59 | -13.72 |
| Net Income | -10.52 | -8.40 | -15.59 | -13.72 |
| Net Income Common Stockholders | -10.52 | -8.40 | -15.59 | -13.72 |
| Total Expenses | 10.54 | 8.83 | 16.16 | 16.70 |
| Interest Income | 0.02 | 0.43 | 0.40 | 2.99 |
| Research And Development | 7.59 | 5.60 | 13.01 | 9.90 |
| Selling General And Administration | 2.95 | 3.23 | 3.16 | 6.80 |
| Normalized EBITDA | -10.54 | -8.83 | -16.16 | -16.70 |
| Normalized Income | -10.52 | -8.40 | -15.59 | -13.72 |
| Basic EPS | -4.15 | -3.04 | -4.11 | -1.85 |
| Diluted EPS | -4.15 | -3.04 | -4.11 | -1.85 |
| Tax Effect Of Unusual Items | 0 | 0 | 0 | 0 |
| Tax Rate For Calcs | 0 | 0 | 0 | 0 |
| Total Unusual Items | 0 | 0 | 0 | 0 |
| Total Unusual Items Excluding Goodwill | 0 | 0 | 0 | 0 |
| Net Income From Continuing Operation Net Minority Interest | -10.52 | -8.40 | -15.59 | -13.72 |
| Net Interest Income | 0.02 | 0.43 | 0.40 | 2.99 |
| Net Income From Continuing And Discontinued Operation | -10.52 | -8.40 | -15.59 | -13.72 |
| Total Operating Income As Reported | -10.54 | -8.83 | -16.16 | -16.70 |
| Diluted Average Shares | 2.54 | 2.76 | 3.79 | 7.41 |
| Basic Average Shares | 2.54 | 2.76 | 3.79 | 7.41 |
| Diluted NI Availto Com Stockholders | -10.52 | -8.40 | -15.59 | -13.72 |
| Net Income Including Noncontrolling Interests | -10.52 | -8.40 | -15.59 | -13.72 |
| Net Income Continuous Operations | -10.52 | -8.40 | -15.59 | -13.72 |
| Other Income Expense | 0 | 0 | 0.17 | 0 |
| Other Non Operating Income Expenses | 0 | 0 | 0.17 | 0 |
| Special Income Charges | 0 | 0 | 0 | 0 |
| Net Non Operating Interest Income Expense | 0.02 | 0.43 | 0.40 | 2.99 |
| Interest Income Non Operating | 0.02 | 0.43 | 0.40 | 2.99 |
| General And Administrative Expense | 2.95 | 3.23 | 3.16 | 6.80 |
| Other Gand A | 2.95 | 3.23 | 3.16 | 6.80 |
| Operating Revenue | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| Monopar Therapeutics Inc.this co. | MNPR | $335M | - | 2.43 | -10.0% | - |
| Delcath Systems, Inc. | DCTH | $355M | 145.86 | 3.18 | 2.4% | 294.72 |
| Standard BioTools Inc. | LAB | $346M | - | 0.81 | -17.7% | -2.30 |
| Evolus, Inc. | EOLS | $337M | - | -14.59 | 223.5% | -14.56 |
| Cross Country Healthcare, Inc. | CCRN | $331M |
| - |
| 1.01 |
| -29.4% |
| 12.17 |
| SIGA Technologies, Inc. | SIGA | $325M | 14.16 | 1.63 | 11.7% | 7.02 |
| DiaMedica Therapeutics Inc. | DMAC | $321M | - | 5.71 | -58.4% | -7.61 |
| CapsoVision, Inc. | CV | $319M | - | 22.61 | -190.9% | -12.32 |
| ClearPoint Neuro, Inc. | CLPT | $310M | - | 10.84 | -91.1% | -14.85 |
| Peer Median | - | 80.01 | 2.41 | -23.5% | -4.96 | |